GoBalto gets new CEO as founder Jae Chung steps down

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

GoBalto gets new CEO as founder Jae Chung steps down

GoBalto has appointed Sujay Jadhav as CEO. Jae Chung, former CEO and founder, will manage corporate strategy, sales and business development as president. Most recently, Jadhav was Senior VP of global corporate strategy and development at Model N. "I founded goBalto 5 years ago on the principle that the life sciences industry should not accept the status quo in how clinical studies are started," said Chung in a statement. "Our vision has resonated with numerous leading biopharmaceutical companies and CROs, resulting in strong demand for our cloud-based solution--Tracker 2.0. I'm pleased Sujay is joining team goBalto as our CEO. With Sujay at the helm, I know we'll grow into a world-class solutions provider to tackle the complex terrain of clinical study startup and beyond." Release

goBalto
Sujay Jadhav will take
over as CEO.


Tri-Institutional Therapeutics Discovery Institute
Michael Foley will act as
Tri-I's first director. 


Biotech

Michael Foley has been named director of the new Tri-Institutional Therapeutics Discovery Institute, a collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan-Kettering Cancer Center formed in October. Story

Margaret Glick joined Ventria Bioscience as the vice president of finance. Release

RainDance Technologies appointed Alfred Merriweather as its chief financial officer. Release

Avanish Vellanki and Gregory Chow joined Lorus Therapeutics as the company's chief business officer and chief financial officer, respectively. Release

> Sean Cunliffe joined Sitka Biopharma as the company's CEO. Cunliffe has held senior positions at Angiotech Pharmaceuticals and Neuromed Pharmaceuticals, now Zalicus ($ZLCS). Release

Lophius Biosciences appointed Robert Phelps as its director of business operations. Release

Hemispherx Biopharma appointed Thomas Equels as its new chief financial officer. The company also appointed Adam Pascale as its chief accounting officer. Release

Tute Genomics appointed Mingfu Zhu as its director of bioinformatics. Release

Sysmex America brought on Alex Garini in the role of chief financial officer. Release

Albuquerque, NM-based Tyrosine Pharma named Wayne Laslie as its new CEO. Laslie is the former chief operating officer and chief commercialization officer for Myrexis and Myriad Pharmaceuticals. Release

TiGenix has appointed Gri-Cel CEO Dirk Büscher and COO José Terencio to the company's board of directors, replacing Nico Vandervelpen and Joël Jean-Mairet, who resigned from the board. Release

Rainbow Coral announced today that the company has appointed Kimberly Palmer as president and CEO. Palmer, a registered nurse, has served as a business consultant to private surgeons, providing administrative and clinical support for a variety of medical practices for the past 8 years. Release

Tolera Therapeutics has appointed Ashleigh Palmer as president, CEO and board director. Previously, Palmer was vice president of business development at Ohmeda. Release

Byron Hewett has been tapped as the new CEO of SomaLogic. Previously, Hewett was chairman and CEO of BioBehavioral Diagnostics, and, before that, president and CEO of Immunicon. Item

Pharma

Takeda has named GlaxoSmithKline's ($GSK) Christophe Weber as chief operating officer. Weber will make the move in April. Story

Evoke Pharma ($EVOK) appointed Dr. Marilyn Carlson as its chief medical officer and Wayne Alves as its senior director of clinical operations. Release

Glenmark named Philip Gioia president of its North American and global API business. Release

Lundbeck has appointed Jacob Tolstrup as senior vice president for business development and HR. Up until now, Tolstrup has served as vice president for Lundbeck's business development. Release

Celator Pharmaceuticals ($CPXX) has appointed Derek Miller as chief business officer. He joins Celator from Genentech, a member of the Roche Group ($RHHBY). Release

CRO

Celerion has appointed John Horkulak as executive director, Eurasian site operations. Horkulak will lead the efforts to further expand the company's early-phase patient capabilities in Europe and Asia. Release

Aptuit named Jonathan Goldman as the company's new CEO. Prior to Aptuit, Goldman was executive vice president of global strategic and business development at Icon Clinical Research. Release

Diagnostics

> Michael Saporito has been appointed as chief financial officer of Neuro Kinetics. Saporito's most recent post was as vice president at the LifeVest division of Zoll Medical. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.